Shackelford D Paul, Fackler Eric, Hoffman Matthew K, Atkinson Samuel
Department of Obstetrics and Gynecology, The East Carolina University Center for the Advancement of Women's Health, Greenville, USA.
Am J Obstet Gynecol. 2002 Apr;186(4):701-4. doi: 10.1067/mob.2002.121867.
The purpose of this study was to determine whether the topical application of recombinant human platelet-derived growth factor gel influences healing after abdominal wound separation.
A double-blinded randomized placebo-controlled trial was conducted in patients with surgical wound separation.
Ten patients were randomized to treatment, and 11 patients were randomized to placebo. There was no difference between groups with regard to age, initial wound volume, type of surgical procedure, incision, or body mass index. Patients in the placebo group received 47 +/- 24 days of therapy. Patients in the treatment group received 29 +/- 14 days of therapy (P =.057). The wounds of the placebo group closed 54 +/- 26 days after operation. Wounds in the treatment group closed in 35 +/- 15 days (P =.05). Wound closure rates were significantly different, as determined by Kaplan-Meier analysis.
Our preliminary study suggests that the topical application of 0.01% recombinant human platelet-derived growth factor gel accelerates healing of separated surgical wounds. Additional studies will be required to determine comparative efficacy and effectiveness relative to the current clinical practice of wound granulation and secondary closure.
本研究旨在确定局部应用重组人血小板衍生生长因子凝胶是否会影响腹部伤口裂开后的愈合情况。
对手术伤口裂开的患者进行了一项双盲随机安慰剂对照试验。
10名患者被随机分配至治疗组，11名患者被随机分配至安慰剂组。两组在年龄、初始伤口体积、手术类型、切口或体重指数方面无差异。安慰剂组患者接受治疗的时间为47±24天。治疗组患者接受治疗的时间为29±14天（P = 0.057）。安慰剂组伤口在术后54±26天愈合。治疗组伤口在35±15天愈合（P = 0.05）。通过Kaplan-Meier分析确定，伤口愈合率存在显著差异。
我们的初步研究表明，局部应用0.01%重组人血小板衍生生长因子凝胶可加速手术伤口裂开后的愈合。需要进行更多研究以确定相对于当前伤口肉芽形成和二期缝合临床实践的比较疗效和有效性。
